Shares of Biocon slipped over 4 per cent to a low of Rs 243.50 in Wednesday's intra-day trades after the company informed that the US Food and Drug Administration (USFDA) had asked for corrective measures at its Malaysia-based subsidiary post inspection.
At 10:20 AM, Biocon was down 3.5 per cent at Rs 245.50. The counter had seen trades of around 1.1 lakh shares as against the two-week average volume of around 71,000 shares on the BSE. Meanwhile, the S&P BSE Sensex quoted flat around 66,440 level.
Biocon in an exchange...